ProKidney (PROK) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Valneva (VALN) has outperformed ProKidney (PROK) over the past year, losing 40.1% versus a loss of 52.5%. Over five years, PROK leads with a -89.5% price change compared with -91.3% for VALN. Valneva is the larger company by market cap ($490.9 million vs $415.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | VALN |
|---|---|---|
| Share price | $1.04 | $5.16 |
| Market cap | $415.21M | $490.86M |
| 1-day change | -1.89% | -3.82% |
| YTD return | -53.57% | -41.50% |
| 1-year return | -52.51% | -40.14% |
| 5-year return | -89.49% | -91.34% |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-0.61 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $893.00K | — |
| Revenue growth (YoY) | +1075.00% | — |
| Net income (latest FY) | $-68.99M | — |
| Operating margin | -18477.83% | — |
| Net margin | -7725.20% | — |
| 52-week high | $2.65 | $12.18 |
| 52-week low | $0.87 | $4.75 |
| Distance from 52-week high | -60.75% | -57.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +525.00% | +137.98% |
| Average volume | 1.44M | 23.10K |
| Shares outstanding | 209.63M | 95.13M |
| Employees | 231 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VALN has outperformed PROK by 12.4 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
PROK vs VALN FAQ
Which is bigger, ProKidney or Valneva?
Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $415.21M for ProKidney (PROK).
Which stock has performed better over the past year, PROK or VALN?
VALN returned -40.14% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.